TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50%

Elixir Medical’s DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a landmark clinical trial in coronary artery disease (CAD).